Vertex Pharmaceuticals Inc. Files SEC Form 4 for August 27, 2015

Strategic Insights -

In a move that brought attention to the publicly traded company, Vertex Pharmaceuticals Inc. filed a document with the U.S. Securities and Exchange Commission (SEC) on August 27, 2015, detailing changes in the ownership structure of the company. The filing, marked by the SEC file number 0001209191-15-068183, was made by the company's director or officer who holds more than ten percent of a class of equity securities registered under Section 12 of the '34 Act. This filing is one of the many required documents that publicly traded companies submit to the SEC to maintain transparency and accountability.

Key Takeaways:

  • The SEC filing was made by Vertex Pharmaceuticals Inc., a publicly traded company with a SIC code of 2834 for Pharmaceutical Preparations.
  • The filing was made by a director or officer who holds more than ten percent of a class of equity securities registered under Section 12 of the '34 Act.
  • The filing was made on Form 4, which contains information on the reporting person's relationship to the company and on purchases and sales of such equity securities.
  • This filing is one of the many required documents that publicly traded companies submit to the SEC to maintain transparency and accountability.
  • The document was submitted to the SEC's filing system on August 27, 2015, and can be accessed through the SEC's website.

Statistics:

  • The SIC code for Vertex Pharmaceuticals Inc. is 2834, Pharmaceutical Preparations.
  • The company's contact information is 50 NORTHERN AVENUE, BOSTON MA 02210, with a phone number of 6173416393.
  • The SEC file number for this filing is 0001209191-15-068183.
  • The document submitted was on Form 4.

Sources:

  • "Pharma Business Week" August 27, 2015
  • U.S. Securities and Exchange Commission (SEC)
  • Vertex Pharmaceuticals Inc. Form 4 filing (SEC file number 0001209191-15-068183)
  • "Form 4" information from the SEC, accessed through the SEC's website.